$0.4525
0.1028.51%
Last update: Oct 28, 8:34 AM
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc.
RVPHOTCQB
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals fell 96.9% from $11.00 to $0.34, behind the S&P 500's +10.0%. Its worst day was May 13 (−55.7%), and its low came May 15 at $0.33.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.20 beat the $-2.00 estimate on $0.00 revenue.
−7.2% · S&P 500 0.0%
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals closed at its highest level of the year, 32.8% above where the year started.
Story events cover the past 12 months · Times ET
+5.4% · S&P 500 +0.7%
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of
−45.5% · S&P 500 +0.5%
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals shares fell 55.4%, while the S&P 500 fell 0.5%.
−55.4% · S&P 500 −0.5%
EPS of $-0.57 beat the $-1.04 estimate on $0.00 revenue.
−11.0% · S&P 500 −0.3%
EPS of $-0.46 missed the $-0.38 estimate on $0.00 revenue.
+10.8% · S&P 500 +0.8%
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals shares rose 46.6%, while the S&P 500 rose 0.3%.
+46.6%, the year's best day · S&P 500 +0.3%
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals shares rose 30.0%, while the S&P 500 rose 1.8%.
+30.0% · S&P 500 +1.8%
EPS of $-0.19 beat the $-0.51 estimate on $0.00 revenue.
+9.5% · S&P 500 +0.7%
Where it ended: a close of $0.34 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.33).
Nothing in the past 12 months.
All RVPH dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RVPH and SPY from Benzinga historical bars. Not investment advice.
